Publications

European League Against Rheumatism (EULAR) | June 14 - 17, 2017
Madrid, Spain

  • Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04755) as a Potential Topical Treatment for Tendinopathy
    Abstract - Poster

Musculoskeletal Regenerative Medicine and Biology: From Development to Regeneration | May 04 - 06, 2017
St. Louis, MO

  • Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04755) as a Potential Topical Treatment for Tendinopathy
    Abstract - Poster

Osteoarthritis Research Society International (OARSI) | April 27 - 30, 2017
Las Vegas, NV

  • Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04755) as a Potential Topical Treatment for Tendinopathy
    Abstract - Poster

World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases | March 23 - 26, 2017
Florence, Italy

  • Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04755) as a Potential Topical Treatment for Tendinopathy
    Abstract - Poster

Orthopaedic Research Society (ORS) | March 19 - 22, 2017
San Diego, CA

  • Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04755) as a Potential Topical Treatment for Tendinopathy
    Abstract - Slides

American College of Rheumatology (ACR) | November 11 - 16, 2016
Washington D.C.

  • Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04755) As a Potential Topical Treatment for Chronic Tendinopathy
    Abstract - Poster

Royal Society of Medicine's 13th Medical Innovations Summit | September 17, 2016
London, United Kingdom

  • Samumed's Regenerative Medicine Platform
    Slides

Overview: Tendinopathy

Tendinopathy is the clinical diagnosis of pain, swelling, and impaired performance of the tendon, the tissue that connects muscle to bone.1,2

  • Tendinopathy can encompass both inflammation of the tendon (tendinitis) and degeneration of the tendon (tendinosis).
  • Epicondylitis, or pain in the wrist extensor tendons in the elbow, affects 1-3% of the population, with 10% of cases refractory at 6 months progressing to surgery.3
  • The Achilles tendon at the ankle and the patellar tendon of the knee are also frequently affected.2

The Wnt pathway may play a role in the disease process of tendinopathy. In human studies and animal models of the disease, overexpression of Wnt proteins has been demonstrated.4,5

  • The Wnt pathway is involved in the processes that determine if mesenchymal stem cells become tendon cells.
  • Activated Wnt signaling has been shown to direct tendon derived stem cells away from a tendon cell fate.4 Additionally, activated Wnt signaling may lead to increased production of degradative proteases that contribute to the breakdown of tendon tissue.5

Inhibition of the Wnt pathway is a potential therapeutic target for the treatment of tendinopathy.

References

    1. Khan KM, Cook J, Bonar F, et al. Histopathology of common tendinopathies: update and implications for clinical management. Sports Med. 1999;27:393-408.
    2. Maffulli N, Wong J, Almekinders LC. Types and epidemiology of tendinopathy. Clin Sports Med. 2003;20:675-92.
    3. Kaux JF, Forthomme B, Goff CL, et al. Current opinions on tendinopathy. J Sports Sci Med. 2011;10(2):238-53.
    4. Liu P, Lee YW, Wong YM, et al. Expression of Wnt pathway mediators in metaplasic tissue in animal model and clinical samples of tendinopathy. Rheumatology. 2013;52:1609-18.
    5. Jelinsky SA, Rodeo SA, Li J, et al. Regulation of gene expression in human tendinopathy. BMC Musculoskelet Disord. 2011;12:86.